PMCB
PharmaCyte Biotech·NASDAQ
--
--(--)
--
--(--)
Latest data update time: Updated on 2026-02-07
Latest data update time: Updated on 2026-02-07
4.39 / 10Overall Score
NeturalInvestment Rating
4.39 / 10Overall Score
NeturalInvestment Rating
Is PMCB a Good Buy Right Now?
- Based on a composite score of 4.39/10, we rate PMCB as a Netural. Our analysis breaks down into 4.83/10 for Fundamentals, 1.42/10 for Technicals, and 6.93/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Technical Analysis of PMCB?
Is PMCB undervalued or overvalued?
Is money flowing into or out of PMCB?
Is PMCB a Good Buy Right Now?
- Based on a composite score of 4.39/10, we rate PMCB as a Netural. Our analysis breaks down into 4.83/10 for Fundamentals, 1.42/10 for Technicals, and 6.93/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Is PMCB undervalued or overvalued?
Technical Analysis of PMCB?
Is money flowing into or out of PMCB?
